FDMT Earnings Date: Nov 10, 2026 (Estimated) — 4D Molecular Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is FDMT's next earnings date?
4D Molecular Therapeutics, Inc. (FDMT) is expected to report earnings on Tuesday, November 10, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.04 on revenue of $4.1M.
How did FDMT do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), 4D Molecular Therapeutics, Inc. posted EPS of -$1.04 versus the -$1.02 estimate, a miss of 2.0%. Revenue was $3.8M against a $3.6M estimate. The stock's 1-day post-earnings move was +4.6%.
How much does FDMT stock move after earnings?
FDMT beat EPS estimates in 1 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.1% (up or down) in the day after earnings.
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -1.02 | -1.04 | -1.96% | $3.8M | ❌ Miss | +4.64% | +38.20% | +18.11% |
| 2026-05-19 | Q1 2026 | -0.99 | -1.01 | -2.02% | $3.0M | ❌ Miss | +0.77% | +5.29% | +14.93% |
| 2026-03-18 | Q4 2025 | -0.53 | 0.43 | +181.13% | $85.1M | ✅ Beat | +4.91% | +15.42% | +22.55% |
| 2025-11-10 | Q3 2025 | -1.00 | -1.01 | -1.00% | $90,000 | ❌ Miss | -3.14% | +2.76% | +0.10% |
| 2025-08-11 | Q2 2025 | -0.77 | -0.98 | -27.27% | $15,000 | ❌ Miss | -1.78% | +28.95% | +23.80% |
| 2025-05-08 | Q1 2025 | -0.86 | -0.86 | +0.00% | $14,000 | ➖ Inline | -4.94% | -1.23% | +47.84% |
| 2025-02-28 | Q4 2024 | -0.83 | -0.90 | -8.43% | $1,000 | ❌ Miss | -8.61% | -10.15% | -28.70% |
| 2024-11-13 | Q3 2024 | -0.70 | -0.79 | -12.86% | $3,000 | ❌ Miss | +4.02% | +9.08% | -15.69% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $3.8M total
| Segment | Share | Revenue | YoY | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 |
|---|---|---|---|---|---|---|---|
| JAPAN | 97.6% | $3.7M | — | — | — | — | — |
| UNITED STATES | 2.4% | $90K | — | — | $28K | $5K | $3K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.